Author:
,Mohammed S. R.,Abdel-Moneim A., ,Abdel-Reheim E. S., ,Ramadan H., ,Eldin Z. E., ,El-Shahawy A. A. G., ,Yousef A. I.,
Abstract
Nanotechnology can offer various non-invasive and efficient alternative delivery strategies for insulin injections to enhance the quality of life of diabetic patients. The current research was aimed to fabricate a de novo oral formula of insulin-loaded chitosan nanoparticles coated with dextrin and pectin (INS-CN/DP) to improve the bioavailability and therapeutic efficiency of oral insulin. INS-CN/DP nano-formula was prepared using ionic gelation technique and characterized by XRD, FTIR, SEM, EDX, and DLS. Insulin loading capacity and entrapment efficiency (LC%, EE%), release profile, and kinetic study was conducted for INS-CN/DP nano-formula. Next, hypoglycemic and antidiabetic efficiency of INS-CN/DP nano-formula were studied in streptozotocin-induced diabetic rats by measuring fasting and postprandial glucose, the activities of carbohydrate metabolizing enzymes, liver glycogen content, and gene expression levels of glucokinase and Glucose transporter-2. Characterization results confirmed the formation of INSCN/DP nanoparticles with LC% =26.2 ± 0.56 and EE% 69.3 ± 2.75, respectively. Size average was 282.8 nm and nearly 25% of loaded insulin released after 4 hrs vs 48% for unloaded insulin. In vivo results displayed that oral administration of INS-CN/DP nanoparticles showed highly significant hypoglycemic and antidiabetic efficacy in diabetic rats compared to unloaded oral insulin. Oral INS-CN/DP nano-formula is promising alternative for insulin injections and can be suggested as non-invasive and effective diabetes therapy
Publisher
Virtual Company of Physics
Reference55 articles.
1. [1] F. Bahman, K. Greish, S. Taurin, Pharmaceutical nanotechnology, 7, 2, 113-128 (2019); https://doi.org/10.2174/2211738507666190321110721
2. [2] E. Choi et al., Scientific Reports,13, 1, 11725 (2023); https://doi.org/10.1038/s41598-023- 29106-w
3. [3] M. S. Alai, W. J. Lin, S. S. Pingale, Journal of food and drug analysis, 23, 3, 351-358 (2015); https://doi.org/10.1016/j.jfda.2015.01.007
4. [4] K. Ji et al., Med-x, 1, 1, 7 (2023).
5. [5] N. A. Peppas, N. J. Kavimandan, European Journal of Pharmaceutical Sciences, 29, 3-4, 183- 197 (2006); https://doi.org/10.1016/j.ejps.2006.04.014